Reimbursed Care Access in Palau

Currently classified as a strictly controlled substance under Palau’s national drug scheduling framework (Title 34 PNC schedules as referenced in the Palau Penal Code), with no authorized medical use outside of approved clinical research. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Palau’s statutory framework references controlled-substance schedules that cover MDMA-class compounds. #

There is no publicly available evidence of a Palau national regulatory approval or a national reimbursement program for intranasal esketamine (Spravato) for psychiatric indications. Palau’s controlled‑substances/scheduling framework governs psychoactive and controlled medicines and allows medical/regulated use of scheduled substances under medical supervision, but national-level public reimbursement arrangements for esketamine are not documented in Palau sources. For context: esketamine (Spravato) has regulatory authorization for treatment‑resistant depression in other jurisdictions (U.S. FDA approval cited here for reference) but that approval does not imply Palau coverage. #. For reference about esketamine regulatory status in jurisdictions where it is approved: #

Ketamine is an established, internationally recognised medical anaesthetic and analgesic that is included on the WHO Model List of Essential Medicines for anaesthesia, and many national health systems permit its use under medical supervision. #. Palau’s legal framework references controlled‑substance schedules and defines medical possession/use under regulation (Title 34 schedules referenced in the Palau Penal Code), which is the statutory mechanism that would permit medically supervised ketamine administration in clinical settings; however, there is no publicly available documentation indicating a Palau national reimbursement policy specific to ketamine for psychiatric indications (e.g., off‑label use for depression) or that ketamine infusion services are covered by a national public insurer. Clinicians in Palau treating patients with ketamine would be expected to do so under standard medical regulation and local facility policy rather than under a documented national reimbursement pathway. # #.

Currently classified as a strictly controlled substance under Palau’s scheduling framework with no authorized medical use outside of approved clinical research. Palau’s schedules and national drug-control laws cover controlled tryptamines such as DMT. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research in Palau. The national scheduling framework is the operative statutory control for novel and classic tryptamines. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no documentation of sanctioned clinical/medical programs or national reimbursement for ibogaine in Palau. #

The active constituents of ayahuasca (DMT and related tryptamines) are controlled under Palau’s scheduling framework; consequently ayahuasca preparations and their psychoactive ingredients have no authorised medical use outside regulated clinical research. Traditional or sacramental exemptions are not documented in Palau law sources. #

Mescaline is a controlled phenethylamine-type substance in many national schedules and is specifically referenced in broad controlled‑substance lists; Palau’s scheduling framework covers mescaline-class substances and there is no authorised medical use or reimbursement for mescaline outside approved research. #

Compounds of the 2C family and related designer phenethylamines are routinely controlled under broad scheduling provisions in national laws; in Palau these analogues/family members are covered by the controlled‑substance scheduling framework and have no authorised medical use outside approved clinical research. #